Breakout Ventures’ Post

𝗦𝘆𝗻𝗕𝗶𝗼 𝗳𝗿𝗼𝗺 𝗟𝗮𝗯 𝘁𝗼 𝗠𝗮𝗿𝗸𝗲𝘁: 𝗩𝗖 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗼𝗿 𝗗𝗲𝗲𝗽 𝗧𝗲𝗰𝗵 𝗦𝘁𝗮𝗿𝘁𝘂𝗽𝘀 Synthetic biology (#SynBio) isn't just about science; it's also about how these scientific innovations are turned into products and solutions that meet market needs. Its applications are extensive, ranging from enhancing food flavors to revolutionizing carbon sequestration practices through innovative uses of natural systems and genetic engineering. However, the path from #lab to #market can be challenging for #founders, from building a scalable plan to navigating regulatory matters. We had the pleasure of hosting Chloë Payne, Principal at Ponderosa Ventures, to cover the basics of the SynBio industry and help aspiring #STEM founders take their first steps into #entrepreneurship. Key themes covered: 🧬 Understanding Synthetic Biology (SynBio) and Its Applications 🗺️ Navigating Regulatory Scenarios in the Food Industry 🎯 Pricing Strategy Basics for SynBio Innovations 📈 Capital Efficiency and Scalability in Synthetic Biology Innovation 🎯 Green Lights and Red Flags for VCs in Early-Stage SynBio > Catch the full conversation here: https://lnkd.in/ebQp34tm #startup #startups #innovation #technology #manufacturing #industry #vcs #venturecapital #techtransfer #deeptech #hardtech #industry #tech #strategy #founders #technology #phd #science #foodtech #biotech #DeepTechCatalyst ----- 📣 Follow The Scenarionist to get exclusive insights at the intersection of Deep Tech and Venture Capital, every week!

We invested in Nextmol 💫 🚀 Nextmol offers a SaaS computational lab that accelerates R&D in specialty chemicals by reducing time and cost through advanced molecular modeling and AI. Discover more about Nextmol 👇

🔬 How is technology transforming the biotech industry? Our latest video dives into the pivotal trends and innovations shaping biotech's future. What you'll discover: ✨ Breakthrough technologies revolutionizing the biotech landscape 🔎 Insights into the impact of these trends on the industry 🌱 Startups aiming to innovate and redefine biotech Check out the full video and share your thoughts on the future of biotech in the comments! 💬 📹 Watch now: https://bit.ly/3WFRE2N #Biotech #Biotechnology #TechTrends #FutureOfBiotech #InnovationInBiotech

🚀DEALFLASH - WEEK 43🚀 An overview of early-stage deals in European bio-, health- and life sciences. pre-seed. 📝intonate. Scope: intonate integrates artificial intelligence into the medical treatment process and reduces administrative effort. Investors: S2S Ventures Ticket size: USD 25k 🐶Televet Scope: Telehealth & scheduling software for veterinarians Investors: Berkeley SkyDeck Ticket size: EUR 145k seed. 📊Viseur AI Scope: Viseur AI delivers a cutting-edge medical imaging solution powered by artificial intelligence. Investors: Kayacan Ventures Ticket size: n/a ⚙️AM 4 AM Scope: AM 4 AM to the creation of novel additive manufacturing materials. Investors: EIT RawMaterials, Luxembourg Space Sector Development fund Ticket size: EUR 1.3 MM 🧪4Tissue Scope: 4Tissue is a research and clinical development firm that develops solutions to solve the limitations of cell-based therapies. Investors: angel investors Ticket size: EUR 2 MM ⚗️autarkize Scope: autarkize scales a market-ready system technology with which a high-quality gas made of methane and hydrogen is extracted. Investors: Fair Capital Partners, Floris Capital GmbH, HTGF | High-Tech Gründerfonds, Innovation for Impact, Interface Capital & angel investors Ticket size: EUR 2.3 MM 💊Epitopea Scope: Epitopea is a transatlantic cancer immunotherapeutics company. Investors: adMare BioInnovations, Advent Life Sciences, Cambridge Innovation Capital, CTI Life Sciences Fund, Fonds de solidarité FTQ, Harrington Discovery Institute at University Hospitals , Investissement Québec, IRICoR, Novateur Ventures Inc. Ticket size: USD 31 MM other. 🤖FarmDroid Scope: FarmDroid is a ground robot that helps farmers and plant growers reduce the cost of crops while making CO2 neutral and organic. Investors: Convent Capital, EIFO, Navus Ventures B.V. Ticket size: DKK 80 MM 🔬Dunia Scope: Dunia Innovations is a Breakthrough materials for tomorrow's net zero planet. Investors: Anglo American, Deep Science Ventures, Elaia, European Innovation Council and SMEs Executive Agency (EISMEA), Kindred Capital VC, Pace Ventures, redalpine, Sequoia Capital & angel investors Ticket size: USD 11.5 MM Looking for easier and more successful fundraising in bio-, health- and life sciences? Contact us at hello@ensemblate.com. #innovation #lifesciences #fundraising #venturecapital

⚙️ 💥 WE Life Sciences, how does it work and how do we operate?   📈 WE Life Sciences plays a key role in the financial support of the life sciences sector in Wallonia, accompanying biotech or medtech companies throughout their life cycle, from the start-up phase to maturity.   🧪 Thanks to a network of experts and international investors, we are involved at every stage of innovation: from preclinical research to the marketing of products or molecules. Our support enables companies to overcome critical obstacles and increase their attractiveness to private investors. This approach strengthens innovative ecosystems and maximises the chances of success on a global scale.   🚀 A new or ongoing Life Sciences project? Get in touch with our team of investors! (link in comment of this post) 👇   #lifesciences #biotech #medtech #innovation #startup Gery Lefebvre Wallonie Entreprendre

Lithuanian startup Biomatter recently secured €6.5 million in seed funding to advance its generative AI platform for enzyme design. The funding round was led by Inventure and UVC Partners, with participation from existing investors and industry experts. This significant investment will enable Biomatter to enhance its technology and accelerate the development of novel enzymes for various applications. Biomatter, founded by Donatas Repečka, Laurynas Karpus, Rolandas Meškys, and Vykintas Jauniskis, focuses on creating new proteins and enzymes using AI, aiming to revolutionize industries such as health, sustainable manufacturing, and agriculture. Their technology offers a more efficient approach to enzyme design, overcoming traditional trial-and-error methods and broadening potential applications. Biomatter has already partnered with notable companies like Thermo Fisher Scientific and BASF to produce unique enzymes. With the newly raised funds, Biomatter plans to expand its platform capabilities and meet increasing customer demand. Their goal is to push the boundaries of enzyme design, contributing to advancements in medicine, chemical manufacturing, and food production. This investment marks a significant step forward in the development of AI-driven synthetic biology.

Do you know the cost of 1 million MAN-YEARS ? I know we have heard the phrase, 'a million years ago' and a lot of times we refer it to historical things happened in the past. Can you imagine if we can save a MILLION MAN YEARS and put it into use to disrupt a system ? We at Bversity are working on reducing the existing 2 years Masters program into 1 year focussed Post-graduate programme serving 1 million students across the world. These 1 million man years saved from the existing 2-year system is so precious to the #biotech & #lifescience industry. To save 1 million man years is our mission ! #biotech #startup #impact

Techbio startups play at the most exciting and bullish end of the healthcare spectrum, researching the world’s most complex diseases and ailments. But following a flurry of funding activity, how are European biotech’s faring in 2024? Where are scaleups going next? And what’s next for the sector? Our CEO and cofounder Nicolas Wolikow will be leading a roundtable discussion at Sifted Summit on October 2nd at 13:10, titled Techbio 2024: The state of play, dissected #biotech #techbio #healthtech #startup

Applications for BioWell 's inaugural cohort are open. They are looking for startups with technology readiness levels (TRL) between 3 to 5 and focus on developing solutions with low-cost, sustainable feedstocks, commercially viable yields and interested in bringing technologies to market in close collaboration with key corporate partners. If this sounds like your startup's next big step, apply by May 15, 2024! Learn more biowell.org/accelerator #StartupOpportunity #BioTech #Sustainability #Innovation #AcceleratorProgram

Briefly Bio launches with $1.2m Pre-Seed Funding to Make Complex Lab Experiments Reproducible Briefly Bio, a biotech startup simplifying complex lab processes, has launched with $1.2 million in pre-seed funding. Co-founded in 2022 by Harry Rickerby, Katya Putintseva, and Staffan Piledahl, the company has launched innovative software to make lab work easily reproducible. It allows scientists to capture their work clearly and share it consistently. According to the company’s announcement reported by Health Tech Digital, the pre-seed round was spearheaded by Compound VC, with a significant contribution from Tiny VC, NP-Hard Ventures, and multiple angel investors from the biotechnology and technology sectors. Read more: https://lnkd.in/gwnd-Jzt #fundingnews #FundingOpportunity #StartupFunding #PreSeed #StartupSuccess #HealthcareNews #LabTechnology #HealthcareFunding #nextdigitalhealth #Wi4 #vineetagrawal